Catheter Precision Q2 revenue up 128% YoY to $212K; net loss $5.4M with $3.2M non-cash

Catheter Precision, Inc.

Revenue $212K for Q2 2025 vs $93K in Q2 2024, 128% increase; sequential growth 48%.
Net loss $5.4M for Q2 includes $3.2M non-cash charges; cash $838K at June 30.
Received CE Mark for LockeT product; European sales expected to start in Q3 2025.
Completed acquisition of Cardionomic heart failure assets via 82%-owned subsidiary Cardionomix.
Formed Kardionav JV for implant-based software to locate ventricular tachycardia ablation sites.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.